II. Indications (age 10 years old or older)

  1. Serotype B Meningococcal Meningitis exposure
  2. Asplenia
  3. Sickle Cell Disease
  4. Specific immune deficiency

III. Mechanism

  1. Covers only Serotype B Meningococcus
    1. Accounts for one third of meningococcal cases
    2. Serotype B outbreaks are most common in infants and college students
  2. Contrast with Menactra, Menveo and Menomune which cover serotypes A, C, W and Y
    1. Indicated for all U.S. children as part of the Primary Series

IV. Preparations (FDA approved in 2014)

  1. Must use same preparation for both doses
  2. MenB-FHbp (Trumenba)
    1. Three dose series (0, 2 and 6 months)
    2. Two dose regimen (0 and 6 months)
      1. Two dose regimen may be used for healthy patients ages 16-23 years AND
      2. Not at increased meningococcal disease
  3. MenB-4C (Bexsero)
    1. Two dose series (0 and 1-6 months)

V. References

  1. Jacobson (2017) Vaccine Update,Mayo Clinic Reviews, Rochester, MN
  2. (2015) Presc Lett 22(10): 59
  3. Ackerman (2015) Am Fam Physician 92(6): 460-8 [PubMed]
  4. Cohn (2013) MMWR Recomm Rep 62(RR-2):1-28 [PubMed]

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window